Mirati Therapeutics Inc Revenue Growth Rates (MRTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Mirati Therapeutics Inc   (NASDAQ: MRTX)
 

MRTX's Revenue Growth by Quarter and Year

Mirati Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRTX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 16.40
2nd Quarter June 13.69
1st Quarter March 7.17
FY 37.26

MRTXs Annual Revenue
Mirati Therapeutics Inc 's Revenue in the fiscal year 2022 $ 12.44 millions
Mirati Therapeutics Inc 's Revenue in the fiscal year 2021 $ 72.09 millions
Mirati Therapeutics Inc 's Revenue in the fiscal year 2020 $ 13.40 millions
Mirati Therapeutics Inc 's Revenue in the fiscal year 2019 $ 3.34 millions
Mirati Therapeutics Inc 's Revenue in the fiscal year 2018 $ 12.93 millions




MRTX Revenue third quarter 2023 Y/Y Growth Comment
Mirati Therapeutics Inc achieved in the third quarter 2023, above Company average Revenue surge of 202.03% year on year, to $ 16.40 millions.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 32 other companies have achieved higher Revenue growth. While Mirati Therapeutics Inc ' s Revenue doubling of 202.03% ranks overall at the positon no. 127 in the third quarter 2023.


MRTX Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 210 % -82.46 % 222.64 %
3rd Quarter September 202.03 % -92.44 % 528.63 % 1053.54 %
2nd Quarter June 155.41 % - - -
1st Quarter March 909.86 % - - -78.23 %
FY   - -82.76 % 437.99 % -

Financial Statements
Mirati Therapeutics Inc 's third quarter 2023 Revenue $ 16.40 millions MRTX's Income Statement
Mirati Therapeutics Inc 's third quarter 2022 Revenue $ 5.43 millions Quarterly MRTX's Income Statement


MRTX Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - -82.87 % -99.58 % -85.03 %
3rd Quarter September 19.8 % 1.31 % - -
2nd Quarter June 90.93 % 654.93 % - -
1st Quarter March 670.97 % 136.67 % - -49.06 %
FY (Year on Year)   - -82.76 % 437.99 % -


Back to MRTX Growth rate Comparisons >> Back to MRTX Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #60
Overall #127

Revenue Y/Y Growth Statistics
High Average Low
1056.28 % 190.33 % -100 %
(Sep 30 2020)   (Mar 31 2021)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #60
Overall #127
Revenue Y/Y Growth Statistics
High Average Low
1056.28 % 190.33 % -100 %
(Sep 30 2020)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Mirati Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
667.34 % 50.76 % -100 %
(Mar 31 2023)  


MRTX's III. Quarter Q/Q Revenue Comment
Mirati Therapeutics Inc achieved in the III. Quarter 2023 below company average Revenue jump of 19.8% quarter on quarter, to $ 16.40 millions.

III. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.31% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Mirati Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 496.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #76
Healthcare Sector #155
Overall #496
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #76
Healthcare Sector #155
Overall #496
Revenue Q/Q Growth Statistics
High Average Low
667.34 % 50.76 % -100 %
(Mar 31 2023)  


MRTX's III. Quarter Q/Q Revenue Comment
Mirati Therapeutics Inc achieved in the III. Quarter 2023 below company average Revenue jump of 19.8% quarter on quarter, to $ 16.40 millions.

III. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.31% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Mirati Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 496.


Mirati Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 38.19 $ 27.22 $ 18.89 $ 12.44 $ 11.80
Y / Y Revenue Growth (TTM) 223.63 % -65.17 % - - -
Year on Year Revenue Growth Overall Ranking # 3647 # 2751 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 40.29 % 44.08 % 51.93 % 5.38 % -84.9 %
Seq. Revenue Growth (TTM) Overall Ranking # 3687 # 3760 # 3047 # 2370 # 3691


Cumulative Revenue growth Comment
With 223.63% annual Revenue growth, Mirati Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2023.

In the Healthcare sector 541 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2751 to 3647.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 210
Healthcare Sector # 542
Overall # 3647

Revenue TTM Y/Y Growth Statistics
High Average Low
223.63 %
 79.23 %
-65.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 210
Sector # 558
S&P 500 # 3687
Cumulative Revenue growth Comment
With 223.63% annual Revenue growth, Mirati Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2023.

In the Healthcare sector 541 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2751 to 3647.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 210
Healthcare Sector # 542
Overall # 3647

Revenue TTM Y/Y Growth Statistics
High Average Low
223.63 %
79.23 %
-65.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 210
Sector # 558
S&P 500 # 3687




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Lexicon Pharmaceuticals Inc 315.38%$ 315.385 millions
Invo Fertility Inc 314.28%$ 314.283 millions
Ss Innovations International Inc313.11%$ 313.110 millions
Capricor Therapeutics inc 288.66%$ 288.662 millions
Longduoduo Co Ltd281.95%$ 281.954 millions
Celldex Therapeutics inc 272.73%$ 272.727 millions
Palvella Therapeutics Inc 263.50%$ 263.501 millions
Ataibeckley Inc 262.50%$ 262.500 millions
Axsome Therapeutics Inc 243.08%$ 243.077 millions
Ascendis Pharma A239.70%$ 239.699 millions
Arcturus Therapeutics Holdings Inc 237.65%$ 237.647 millions
Verve Therapeutics Inc 235.52%$ 235.522 millions
Shattuck Labs Inc 223.58%$ 223.585 millions
Clearside Biomedical Inc 222.93%$ 222.932 millions
Serina Therapeutics Inc 222.22%$ 222.222 millions
Marinus Pharmaceuticals Inc 213.59%$ 213.590 millions
Hookipa Pharma inc 207.94%$ 207.937 millions
Mirati Therapeutics Inc 201.97%$ 201.970 millions
Roivant Sciences Ltd 196.03%$ 196.026 millions
Pressure Biosciences Inc 186.74%$ 186.742 millions
Alnylam Pharmaceuticals Inc 183.96%$ 183.963 millions
Universal Biosensors Inc 181.66%$ 181.659 millions
Inmed Pharmaceuticals Inc181.13%$ 181.129 millions
Tff Pharmaceuticals Inc167.99%$ 167.994 millions
Foghorn Therapeutics Inc 163.46%$ 163.461 millions
Transmedics Group Inc 158.65%$ 158.654 millions
Anaptysbio Inc 156.61%$ 156.613 millions
Intelligent Bio Solutions Inc 155.72%$ 155.716 millions
Kyntra Bio Inc 155.06%$ 155.062 millions
Mirum Pharmaceuticals Inc 154.13%$ 154.127 millions


About Mirati Therapeutics Inc Revenue Growth Rates (MRTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Mirati Therapeutics Inc (CIK 1576263).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-23-036875
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Mirati Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.